The amblyopia treatment market size is projected to be valued at USD 3,837.2 million in 2023 and is expected to rise to USD 5,582.3 million by 2033. The sales of amblyopia treatment are expected to record a significant CAGR of 3.8% during the forecast period.
Amblyopia, often called lazy eye or lazy vision, is a serious eye condition that affects vision. Poor sight develops in one eye during infancy or childhood and worsens over time if not treated. Early screening is important because treatment is more effective when started early. Treatments include an eye patch or glasses.
Amblyopia occurs when there is a key difference between the two eyes in their ability to focus. The most common cause of amblyopia is other vision problems. Treating these other conditions is important, or the brain starts relying on the eye for better vision, leading to amblyopia.
Atropine sulfate eye drops are used to treat different eye disorders, including amblyopia and cycloplegia. Players in the global amblyopia treatment market are increasing research activities that are focused on preventing potential side effects of these drops, such as difficulty in seeing at night, eye pain, and blurred vision.
North America is considered a highly lucrative market, driven primarily by the presence of many players in the region. Simultaneously, developing countries' lack of resources is a significant growth barrier.
| Attributes | Details |
|---|---|
| Market Estimated Size (2023) | USD 3,837.2 million |
| Market CAGR (2023 to 2033) | 3.8% |
| Market Forecasted Size (2033) | USD 5,582.3 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The growing prevalence of hypermetropia and myopia across the globe is expected to play a key role in driving the market during the forecast period. Players are adopting various innovative methods to advance the treatment method, which is projected to offer remunerative opportunities to the industry in the forthcoming time.
Many healthcare experts are enhancing the application of video games as one of the methods to treat amblyopia Players in the market are focused on increasing awareness through video games as a treatment during the early age in children so that their brains can work with the weaker eye by developing better connections between the eye and brain Such initiatives are expected to propel the market growth in the coming period.
Other factors like increasing demand for eye patches and glasses, computer-based vision therapy, and electronic eyeglasses and lenses that are correct for aniseikonia are expected to develop in the market in the coming time. Increasing focus on technological development for advanced products in amblyopia treatment is likely to offer significant opportunities to the market in the forthcoming period.
Leading players focus on the launch of technologically advanced products for the treatment of amblyopia. This is anticipated to augment the global amblyopia treatment market during the forecast period. In March 2021, NovaSight received the Food and Drug Administration 510(k) clearance for CureSight for the treatment of amblyopia. The device trains the brain to use both eyes simultaneously while the user watches videos through 3D glasses.
A lack of awareness regarding the disorder is expected to hamper the market in the forecast period. Also, the lack of resources in developing countries is anticipated to be another factor limiting market expansion in the forthcoming period.
However, developing healthcare infrastructure and the growing investment of government in evolving economies are expected to act as a significant counter to the hampering causes and propel market growth in the coming time.
Principal Consultant
These patches are a commonly used and effective treatment option for amblyopia, also known as lazy eye. Eye patches work by covering the stronger eye, forcing the weaker eye to work harder and improve its visual acuity. They are typically worn for a certain period each day, as prescribed by an ophthalmologist.
Eye patches are non-invasive and easily accessible, making them a popular choice for amblyopia treatment. They are available in various sizes, designs, and materials to suit the needs and preferences of patients, including children. The use of eye patches as a part of amblyopia treatment reflects their effectiveness in stimulating visual development and improving visual function in the weaker eye.
Pharmacies are a crucial distribution channel in the market. These establishments serve as key intermediaries between manufacturers of amblyopia treatment products and consumers, providing convenient access to necessary medications, eye patches, and other related products.
Pharmacies offer a wide range of amblyopia treatment options, including prescription drugs, over-the-counter medications, and various occlusion therapy tools such as eye patches. They serve as trusted sources of information and guidance for patients and caregivers, providing advice on the proper usage and administration of amblyopia treatment products. Pharmacies also ensure the availability and proper storage of these products, ensuring patients can access them when needed.
As per the analysis, North America is anticipated to dominate the market during the forecast period. In 2022, the region is expected to secure about 38.6% of the global market share. The United States is projected to contribute the maximum to developing the market in the coming period.
The region's domination can be attributed to the presence of key players in the region. Also, the integration of advanced technology to offer better treatment is projected to be another key factor strengthening the regional market in the forecast period. The growth in North America is attributed to factors such as early acceptance of new products, sturdy healthcare infrastructure, the existence of many key players, and increased cases of amblyopia in the region.
Additionally, increasing clearances by FDA to players is expected to augment the market size in the forecast period. In October 2021, Luminopia, a digital therapeutics company, announced that the United States FDA had granted de novo premarket approval for Luminopia One as a prescription therapy to enhance vision in children with amblyopia, the key cause of vision loss in children. Owing to such factors, the market in the region is expected to flourish during the forecast period.
As per the analysis, the European amblyopia treatment market is projected to witness significant growth opportunities in the forecast period. As of 2022, the region is expected to procure about 30.5% of the global market share. The United Kingdom is predicted to significantly contribute to developing the regional market. This can be attributed to the presence of resources, the contribution of key players, and the ongoing development of the treatment.
Acquisitions among players are projected to widen the market size during the forecast period. For instance, in April 2020, Novartis acquired Amblyotech, a United States-based software startup, and in collaboration with Ubisoft and McGill University, may pursue the development of acquired digital technology for the treatment of amblyopia. Such factors are expected to boost the European market in the forecast period.
The country's large population, combined with the increasing prevalence of amblyopia, has created a substantial demand for effective treatment options. The growing awareness about early detection and intervention, coupled with improved healthcare infrastructure, has contributed to the expansion of the market in China. Additionally, advancements in medical technology and increased investment in research and development have led to the development of innovative treatment modalities and therapies.
The government's initiatives to improve eye care services and promote early screening programs have also played a significant role in driving the growth of the Amblyopia Treatment Market in China. As a result, healthcare providers, ophthalmologists, and manufacturers of amblyopia treatment products are focusing on catering to the rising demand in the country and developing targeted strategies to address the specific needs of the Chinese market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some key participants present in the global amblyopia treatment market are Vivid Vision, 3M, Lancastle International Ltd, Johnson and Johnson, Trayner, Good-Lite, HOYA Vision Care Company, Ortopad USA, NovaSight, and Revital Vision, among others.
Attributed to the presence of several leading participants, the market is highly competitive. While global players such as Vivid Vision, 3M, and Lancastle International Ltd account for a considerable market size, several regional-level players are also operating across key growth regions, particularly in the Asia Pacific.
Recent Developments :
| Attributes | Details |
|---|---|
| Growth Rate | CAGR of 3.8% from 2023 to 2033 |
| Base Year of Estimation | 2023 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and Volume in Units and F-CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends, and Pricing Analysis |
| Key Segments Covered | Treatment Type, Distribution Channel, By Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; The Middle East & Africa; Oceania |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, Italy, France, The United Kingdom, Spain, Russia, China, Japan, India, GCC Countries, Australia |
| Key Companies Profiled | Vivid Vision; 3M; Lancastle International Ltd; Johnson and Johnson; Trayner; Good-Lite; HOYA Vision Care Company; Ortopad USA; NovaSight; Revital Vision |
| Customization & Pricing | Available upon Request |
The growth potential of the market is 3.8% through 2033
North America is projected to emerge as a lucrative market.
Europe is expected to procure about 30.5% of the global market share in 2022.
China is likely to expand at a CAGR of 4.6% through 2033.
Vivid Vision, 3M, and Trayner are the key market players.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Eye Patches 5.2. Spectacle Lenses 5.3. Eye Drops & Ointments 5.4. Surgery 5.5. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Pharmacies 6.2. Drug Stores 6.3. Hypermarkets and Supermarkets 6.4. E-Commerce 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Vivid Vision 17.2. 3M 17.3. Lancastle International Ltd 17.4. Johnson and Johnson 17.5. Trayner 17.6. Good-Lite 17.7. HOYA Vision Care Company 17.8. Ortopad USA 17.9. NovaSight 17.10. Revital Vision 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Amblyopia Treatment Market
